| Page 1053 | Kisaco Research

Innovation excites us and unlocks business value but unless it inherently scales profitably, you could be stuck at a dead-end. This talk looks at NVDIMM-N as a cautionary tale of commercialization pitfalls that kill innovative technologies. How can you analyse a technology not just for the value it unleashes but also for its long-term commercial viability? How is CXL different? What types of CXL implementations should you consider and which should you be wary of?

 

CXL
Emerging Memories
Use Case
Hardware Eng.
Memory Systems Eng.
Systems Architecture

Author:

Keith Winkeler

VP of Engineering, PowerEdge & Core Compute Platforms
Dell Technologies

Keith Winkeler is VP of Engineering, PowerEdge & Core Compute Platforms at Dell Technologies. Keith is an accomplished and collaborative executive with 30 years of demonstrated excellence in building and leading high performance global organizations responsible for architectural definition, development and delivery of industry leading HW/SW products. His proven strengths include talent management and development, organizational design, matrixed and global teams, ODM partner leadership and value chain management.

... read more

Keith Winkeler

VP of Engineering, PowerEdge & Core Compute Platforms
Dell Technologies

Keith Winkeler is VP of Engineering, PowerEdge & Core Compute Platforms at Dell Technologies. Keith is an accomplished and collaborative executive with 30 years of demonstrated excellence in building and leading high performance global organizations responsible for architectural definition, development and delivery of industry leading HW/SW products. His proven strengths include talent management and development, organizational design, matrixed and global teams, ODM partner leadership and value chain management.

The leading companies at every level of the data center value chain, from IP, chips, platforms, system OEMs to hyperscalers, are coalescing around CXL technology as a path to revolutionize the data center. With workload demands increasing rapidly, the need for more memory bandwidth and capacity continues to rise. Memory is of critical importance, and its share of the server bill of materials (BoM) continues to grow. Making the best use of vital memory resources is an imperative. With CXL technology, the industry is pursuing tiered-memory solutions that can break through the memory bottleneck while at the same time delivering greater efficiency and improved TCO. Ultimately, CXL technology can support composable architectures that match the amount of compute, memory and storage in an on-demand fashion to the needs of a wide range of advanced workloads.    

CXL
Embedded Memory
Emerging Memories
Hardware Eng.
Memory Systems Eng.
Systems Architecture

Author:

Mark Orthodoxou

VP, Strategic Marketing, Datacenter Product
Rambus

Mark Orthodoxou is the Vice President of Strategic Marketing for Rambus’ Datacenter Products Group. Mark has over 25 years of experience in product management and strategic planning in the semiconductor industry across multiple technology disciplines, including enterprise storage, data center compute, memory subsystems and networking. Mark has evangelized the benefits of serial-attached memory since long before CXL was introduced as a standard and was responsible for the introduction of the first commercially available products in this space. Mark currently sits on the CXL Consortium Marketing Working Group. He has held various leadership positions at Microchip, Microsemi, PMC-Sierra, and IDT.

... read more

Mark Orthodoxou

VP, Strategic Marketing, Datacenter Product
Rambus

Mark Orthodoxou is the Vice President of Strategic Marketing for Rambus’ Datacenter Products Group. Mark has over 25 years of experience in product management and strategic planning in the semiconductor industry across multiple technology disciplines, including enterprise storage, data center compute, memory subsystems and networking. Mark has evangelized the benefits of serial-attached memory since long before CXL was introduced as a standard and was responsible for the introduction of the first commercially available products in this space. Mark currently sits on the CXL Consortium Marketing Working Group. He has held various leadership positions at Microchip, Microsemi, PMC-Sierra, and IDT.

 

Maya Preiswerk

Swiss Head of Sanctions
Banque Lombard Odier

Maya Preiswerk

Swiss Head of Sanctions
Banque Lombard Odier

Maya Preiswerk

Swiss Head of Sanctions
Banque Lombard Odier
 

Jens Pahl, PhD

Senior Scientist Translational Immunobiology
Affimed GmbH

Jens Pahl, PhD

Senior Scientist Translational Immunobiology
Affimed GmbH

Jens Pahl, PhD

Senior Scientist Translational Immunobiology
Affimed GmbH
 

Dr Adil Duru

Senior Research Manager
Glycostem Therapeutics

I received my Ph.D. from the Center for Infectious Medicine (CIM), Karolinska Institutet (KI), Sweden, in 2012 where I studied MHC-class I restricted-peptide based immunomodulation of T cells and NK cells. I moved for my post-doctoral studies at the Center for Hematology and Regenerative Medicine (HERM) at KI with a focus on developing novel cell culture agents and methods as well as genetic modification strategies for ex vivo NK cell expansion.

Read full bio

Dr Adil Duru

Senior Research Manager
Glycostem Therapeutics

Dr Adil Duru

Senior Research Manager
Glycostem Therapeutics

I received my Ph.D. from the Center for Infectious Medicine (CIM), Karolinska Institutet (KI), Sweden, in 2012 where I studied MHC-class I restricted-peptide based immunomodulation of T cells and NK cells. I moved for my post-doctoral studies at the Center for Hematology and Regenerative Medicine (HERM) at KI with a focus on developing novel cell culture agents and methods as well as genetic modification strategies for ex vivo NK cell expansion. In parallel, I investigated the impact of novel immunomodulatory drugs and biological agents on prognosis and treatment of multiple myeloma patients.

From 2015 until 2020, I continued my research as an Assistant Professor/Group Leader at the Nova Southeastern University (NSU) Cell Therapy Institute, FL, USA, in the field of tumor immunology and immunotherapy with a specific interest in investigating NK cell interactions with different primary solid tumour models such as Melanoma and Sarcoma and developing novel TCR- and CAR-based genetically modified NK cell immunotherapies. Furthermore, I established and directed the Cell Therapy Core Facility (CTC) at NSU, which is capable of design, development, pre-clinical evaluation and optimization of cell therapy products. Additionally, I am a cofounder and shareholder of the biotech company Vycellix, which is focused on developing innovative products enhancing the immune responses against cancer.

In 2020, I joined to Glycostem Therapeutics, Netherlands, as senior research manager where I am working to develop novel robust and efficient native and engineered NK cell-based immunotherapy regimens for high-risk cancers.